- Home
- MGTX vs FLGT Comparison
MGTX vs FLGT Comparison
Compare MGTX & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- FLGT
- Stock Information
- Founded
- MGTX 2015
- FLGT 2011
- Country
- MGTX United States
- FLGT United States
- Employees
- MGTX N/A
- FLGT N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- FLGT Medical Specialities
- Sector
- MGTX Health Care
- FLGT Health Care
- Exchange
- MGTX Nasdaq
- FLGT Nasdaq
- Market Cap
- MGTX 670.2M
- FLGT 587.3M
- IPO Year
- MGTX N/A
- FLGT 2016
- Fundamental
- Price
- MGTX $7.51
- FLGT $21.79
- Analyst Decision
- MGTX Strong Buy
- FLGT Buy
- Analyst Count
- MGTX 2
- FLGT 3
- Target Price
- MGTX $24.00
- FLGT $25.33
- AVG Volume (30 Days)
- MGTX 325.1K
- FLGT 205.1K
- Earning Date
- MGTX 08-14-2025
- FLGT 11-07-2025
- Dividend Yield
- MGTX N/A
- FLGT N/A
- EPS Growth
- MGTX N/A
- FLGT N/A
- EPS
- MGTX N/A
- FLGT N/A
- Revenue
- MGTX $37,917,000.00
- FLGT $303,223,000.00
- Revenue This Year
- MGTX $145.67
- FLGT $15.19
- Revenue Next Year
- MGTX $167.61
- FLGT $10.58
- P/E Ratio
- MGTX N/A
- FLGT N/A
- Revenue Growth
- MGTX 366.84
- FLGT 4.31
- 52 Week Low
- MGTX $3.86
- FLGT $14.57
- 52 Week High
- MGTX $8.98
- FLGT $23.56
- Technical
- Relative Strength Index (RSI)
- MGTX 46.65
- FLGT 56.10
- Support Level
- MGTX $7.39
- FLGT $21.50
- Resistance Level
- MGTX $7.91
- FLGT $22.37
- Average True Range (ATR)
- MGTX 0.36
- FLGT 0.53
- MACD
- MGTX 0.01
- FLGT -0.09
- Stochastic Oscillator
- MGTX 39.78
- FLGT 44.78
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.